SCHEMBL278542

SCHEMBL278542

[201Pb]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25437025 1.00
SCHEMBL29420027 0.71
Methane SCHEMBL23929073 0.00
SCHEMBL23462034 0.00
Potassium Ion SCHEMBL23462163 0.00 CA4 (0.50)
SCHEMBL23462133 0.00
SCHEMBL23358113 0.00
Hydrogen Sulfide SCHEMBL23805181 0.00
SCHEMBL23462031 0.00
Potassium Ion SCHEMBL23462161 0.00 CA4 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260069726-A1 ZWITTERIONIC COMPOUNDS AND USES THEREOF UNIV SASKATCHEWAN (CA) 2026-03-12 US claimed
EP-4695306-A2 SINGLE-DOMAIN ANTIBODIES THAT BIND THE CONSTANT REGION OF IMMUNOGLOBULINS Oregon Health & Science University (US) 2026-02-18 EP claimed
US-12479792-B2 Compositions of chelating molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-11-25 US claimed
US-20250326856-A1 HUMANIZED ANTI-CD45 ANTIBODIES AND USES THEREOF Fred Hutchison Cancer Center (US) 2025-10-23 US claimed
EP-3368056-B1 COMPOSITIONS AND METHODS FOR SENSITIZING LOW RESPONSIVE TUMORS TO CANCER THERAPY PANDURANGI RAGHOOTTAMA (US) 2025-08-20 EP claimed
US-20250249125-A1 ANTI-CD90 ANTIBODIES, BINDING FRAGMENTS, AND USES THEREOF Fred Hutchison Cancer Center (US) 2025-08-07 US claimed
WO-2025097015-A1 CLEC2A-BINDING THERAPEUTICS FRED HUTCHINSON CANCER CENTER (US) 2025-05-08 WO claimed
WO-2025080875-A1 CYTOMEGALOVIRUS-DERIVED CD44 BINDING PROTEINS AND USES THEREOF LIONS EYE INSTITUTE (AU) 2025-04-17 WO claimed
US-20250025557-A1 TREATMENTS FOR CANCERS UTILIZING CELL-TARGETED THERAPIES AND ASSOCIATED RESEARCH PROTOCOLS FRED HUTCHINSON CANCER CENTER (US) 2025-01-23 US claimed
EP-3503930-B1 CHELATING PLATFORM FOR DELIVERY OF RADIONUCLIDES FRED HUTCHINSON CANCER CENTER (US) 2024-12-11 EP claimed
WO-2023235772-A2 HUMANIZED ANTI-CD45 ANTIBODIES AND USES THEREOF FRED HUTCHINSON CANCER CENTER (US) 2023-12-07 WO claimed
US-20230331824-A1 SINGLE-DOMAIN ANTIBODIES THAT BIND SARS-COV-2 THE ROCKEFELLER UNIVERSITY (US) 2023-10-19 US claimed
EP-4200328-A2 SINGLE-DOMAIN ANTIBODIES THAT BIND SARS-COV-2 The Rockefeller University (US) 2023-06-28 EP claimed
US-20230190810-A1 ANTI-CD33 ANTIBODIES AND USES THEREOF FRED HUTCHINSON CANCER CENTER (US) 2023-06-22 US claimed
US-20230144405-A1 HUMAN ANTI-CD33 ANTIBODIES AND USES THEREOF FRED HUTCHINSON CANCER CENTER (US) 2023-05-11 US claimed
WO-2023081727-A1 TREATMENTS FOR CANCERS UTILIZING CELL-TARGETED THERAPIES AND ASSOCIATED RESEARCH PROTOCOLS FRED HUTCHINSON CANCER CENTER (US) 2023-05-11 WO claimed
EP-4126248-A2 HUMAN ANTI-CD33 ANTIBODIES AND USES THEREOF Fred Hutchinson Cancer Center (US) 2023-02-08 EP claimed
US-20220160904-A1 CHELATING PLATFORM FOR DELIVERY OF RADIONUCLIDES FRED HUTCHINSON CANCER RESEARCH CENTER (US) 2022-05-26 US claimed
WO-2022040603-A2 SINGLE-DOMAIN ANTIBODIES THAT BIND SARS-COV-2 THE ROCKEFELLER UNIVERSITY (US) 2022-02-24 WO claimed
CN-107606495-A Electric capacity electroluminescent cold light source and preparation method thereof 张俭 2018-01-19 CN claimed